Biopolis S.L.
This study aims to understand the efficacy of two probiotic interventions as prophylaxes of migraine symptoms in individuals diagnosed with episodic migraine. The primary outcome measure will be migraine days per month, but secondary outcome measures such as use of analgesia, the wider impact of migraine (as assessed through the HIT-6 score) will also be assessed. Finally adverse effects will be evaluated. The study will have three arms: two arms including the two different probiotic preparations and a third placebo arm.
Migraine
Probiotic 1
Placebo
Probiotic 2
Not Applicable
Study Type : | Interventional |
Estimated Enrollment : | 75 participants |
Masking : | Double |
Masking Description : | Double-blind |
Primary Purpose : | Treatment |
Official Title : | A Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Two Probiotic Interventions For The Prophylaxis of Migraine in Patients Diagnosed With Episodic Migraine |
Actual Study Start Date : | March 2, 2020 |
Estimated Primary Completion Date : | February 2, 2021 |
Estimated Study Completion Date : | May 2, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Probiotic 1 group A commercially-available multi-strain probiotic with added magnesium and vitamin B6 |
Dietary Supplement: Probiotic 1 |
Experimental: Probiotic 2 group A multi-strain probiotic |
Dietary Supplement: Probiotic 2 |
Placebo Comparator: Placebo group Identical placebo |
Dietary Supplement: Placebo |
Ages Eligible for Study: | 18 Years to 65 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Vinalopó University Hospital
Elche, Alicante, Spain, 03293
Not yet recruiting
Torrevieja University Hospital
Torrevieja, Alicante, Spain, 03186